Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 12:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 247 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Healthy Male and Female Subjects Clear all

Conditions: Healthy
Interventions: MTP-131 (Bendavia™); Drug
Lead sponsor: Stealth BioTherapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Infection, Human Immunodeficiency Virus, HIV Infections
Interventions: GSK1265744 30 mg; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: Lakewood, Colorado • Minneapolis, Minnesota

Conditions: Healthy, Renal Impairment
Interventions: cabozantinib; Drug
Lead sponsor: Exelixis; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 3
States / cities: Miami, Florida • Orlando, Florida • Neptune City, New Jersey

Conditions: Healthy
Interventions: AZD6765; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Healthy Volunteers, Fasting, Fed
Interventions: Apixaban 5 mg Oral Dissolving Film (TAH3311) and Tablet (Eliquis®); Drug
Lead sponsor: TAHO Pharmaceuticals Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Healthy
Interventions: Aliskiren, Valsartan; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2006
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Healthy Volunteer
Interventions: AZD7325; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Relapsing Remitting Multiple Sclerosis
Interventions: Monomethyl Fumarate 190 Mg, Diroximel Fumarate 462 mg; Drug
Lead sponsor: Banner Life Sciences LLC; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Healthy Volunteers
Interventions: ABBV-990, Placebo for ABBV-990; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Grayslake, Illinois

Conditions: Renal Insufficiency
Interventions: PF-04634817; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 2
States / cities: DeLand, Florida • Miami, Florida

Conditions: Hepatic Impairment; Renal Impairment
Interventions: Plasma Sampling; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 3
States / cities: Orlando, Florida • Minneapolis, Minnesota • Knoxville, Tennessee

Conditions: Bioequivalence, Fixed Dose Combination Tablets, Healthy Male and Female Subjects
Interventions: dapagliflozin/metformin XR 5/500 mg test drug (Mount Vernon), dapagliflozin/metformin XR 5/500 mg reference drug (Humacao), dapagliflozin/metformin XR 10/1000 mg test drug (Mount Vernon), dapagliflozin/metformin XR 10/1000 mg reference drug (Humacao); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy
Interventions: AZD5099, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Glendale, California

Conditions: Insomnia
Interventions: 20 mg VEC-162, 50 mg VEC-162, 100 mg VEC-162, Placebo; Drug
Lead sponsor: Vanda Pharmaceuticals; Industry
Eligibility: 21 Years to 50 Years
Enrollment: 411 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 19
States / cities: Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 16 more

Conditions: Healthy
Interventions: Placebo, JNJ-41443532; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Cypress, California

Conditions: Renal Insufficiency, Chronic, Hepatic Insufficiency, Healthy
Interventions: Sporanox, Diclofenac Sodium; Drug
Lead sponsor: Javelin Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 3
States / cities: Orlando, Florida • Minneapolis, Minnesota • Knoxville, Tennessee

Conditions: Renal Impairment, Healthy Volunteers
Interventions: Mobocertinib; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 81 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 2
States / cities: Hialeah, Florida • Orlando, Florida

Conditions: Healthy Volunteer
Interventions: AZD1722, Placebo; Drug
Lead sponsor: Ardelyx; Industry
Eligibility: 19 Years to 65 Years
Enrollment: 83 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Cypress, California

Conditions: Pain
Interventions: Acetylsalicylic acid (Aspirin, BAY1019036); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Hackensack, New Jersey

Conditions: Renal Impairment
Interventions: 100 mg Resmetirom Tablet; Drug
Lead sponsor: Madrigal Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 3
States / cities: Orlando, Florida • Tampa, Florida • Chicago, Illinois

Conditions: Healthy Volunteers
Interventions: iCP-NI, Placebo; Drug
Lead sponsor: Cellivery Therapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Healthy Subjects
Interventions: GSK1247303; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2
Interventions: GSK189075 (Modified and immediate release formulations); Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2007
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Pharmacokinetics of ASKP1240, Healthy Volunteers
Interventions: ASP1240, Placebo; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 109 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

Study to Evaluate Safety, Tolerability, and Pharmacokinetics (PK) of Intravenous (IV) Infusion of MTP-131 (Bendavia™) in Healthy Adults

Pharmacokinetics Study of GSK1265744 in Subjects With Severe Renal Impairment

A Single-Dose Study to Assess the Pharmacokinetics of Cabozantinib (XL184) Capsules in Subjects With Impaired Renal Function

AZD6765 Oral Single Ascending Dose/Multiple Ascending Dose (SAD/MAD)

Comparative Bioavailability Study of TAH3311 5 mg Oral Dissolving Film vs ELIQUIS® 5 mg Tablet in Healthy Volunteers

Bioavailability of Aliskiren and Valsartan as a Single Tablet vs. the Same Doses of the Two Drugs Given Separately to Healthy Subjects.

AZD7325 Multiple Ascending Dose Study

Bioequivalence Study of Bafiertam 190 mg and Vumerity® 462 mg Delayed-Release Capsules in Fasting Healthy Subjects

Study to Assess Adverse Events and How Oral ABBV-990 Moves Through the Body of Adult Healthy Participants

PF-04634817 Renal Impairment Study

Phase 0 Study in Healthy, Hepatic and Renal Impaired Subjects to Obtain Plasma for Lenvatinib Protein Binding

A Study to Assess the Bioequivalence of Dapagliflozin/Metformin XR Fixed-dose Combination Tablets in Healthy Subjects

Clinical Study Assessing the Safety, Tolerability, and Pharmacokinetics of Intravenous AZD5099 in Healthy Subjects

VEC-162 Study in Healthy Adult Volunteers in a Model of Insomnia

JNJ-41443532 Sex, Race, and Age Pharmacokinetic (PK) Study

Open-Label, Single-Dose Study to Evaluate the Safety and PK of DIC075V in Subjects With Renal Insufficiency and Hepatic Impairment Compared to Healthy Subjects and Evaluate the Safety and Pharmacokinetics of HPβCD When Administered in DIC075V Compared to Sporanox® in Healthy Subjects

A Study of Mobocertinib Capsules in People With Severe Kidney Problems and People With Healthy Kidneys

Safety, Tolerability, Pharmacokinetics and Pharmacodynamic of AZD1722 in Healthy Male and Female Japanese Subjects

Bioequivalence of Single Dose Fast Release Aspirin (1000 mg) Tablet Versus Single Dose of Two 500 mg Fast Release Aspirin Tablets

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses (6 Days) of 100 mg Resmetirom in Subjects With Severe Renal Impairment and in Matched Healthy Control Subjects With Normal Renal Function

iCP-NI - Safety, Tolerability, Pharmacokinetic, and Immunogenicity Study in Healthy Male and Female Subjects

GSK1247303 First Time in Human Study

A Study to Compare the Safety and Drug Levels in Blood When Using Various Forms of GSK189075 Given to Healthy Subjects

Study of ASKP1240 After a Single Intravenous Dose at Escalating Dose Levels in Healthy Subjects